NCT07215312
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
Active, Not Recruiting
PHASE2Ages 18–70InterventionalTreatmentEli Lilly and Company
~100 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:LY3938577Degludec
At a glance
Recruiting sites
0 of 26 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis)
Measured over Baseline through Week 20
Conditions
Where it's being run
26 sites across 12 statesTexas6
Argentina6
Florida4
California2
Arizona1
Iowa1
Missouri1
North Carolina1
Study leadership
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Have type 2 diabetes
Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening
Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive
Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)
Exclusion
Have type 1 diabetes
What this trial measures
- Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis)Baseline through Week 20